Purchase this article with an account.
M-J Chen, S Lin, RL Stamper; Efficacy and Safety of Bimatoprost as Additive and Replacement Therapy in Patients Uncontrolled With Latanoprost: Early Results . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3411.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To determine the efficacy and safety of bimatoprost when used in addition to or as replacement for latanoprost. Methods: We undertook a retrospective analysis of patients on maximally tolerated medications in whom bimatoprost was used as adjunctive or replacement therapy for latanoprost. Thirty nine patients were enrolled in this study. Of these, 13 (Group A) used bimatoprost as add-on therapy and 26 (Group B) received it as replacement therapy for latanoprost. Intraocular pressure (IOP) was recorded pre-bimatoprost treatment and at each follow-up visit. Demographic data and adverse events were obtained through chart review and analyzed. Results: During the study period, 4 (30.8%) in Group A and 5 (19.2%) in Group B reported an adverse event that led to discontinuation of treatment with bimatoprost. In Group A, bimatoprost lowered IOP from an average of 21.29 ± 2.88 mmHg to 16.21 ± 2.35 mmHg after 3.02 ± 2.12 months of follow-up. The mean IOP reduction was 5.08 ± 3.18 mmHg which was statistically significant (P < 0.001). In Group B, bimatoprost lowered IOP from an average of 16.98 ± 2.89 mmHg to 15.65 ± 3.24 mmHg after 2.45 ± 1.43 months of follow-up. The mean IOP reduction was 1.33 ± 2.06 mmHg which was statistically significant (P = 0.005). Conclusion: When tolerated, bimatoprost demonstrated an additional IOP reduction of 5.08 mmHg as adjunctive therapy and 1.33 mmHg as replacement therapy in this patient population at last follow-up visit. For those patients on maximally tolerated medications, bimatoprost may provide short-term significant IOP lowering as adjunctive or replacement therapy for latanoprost.
This PDF is available to Subscribers Only